 Mutations in the epidermal growth factor receptor activate signalling pathways that promote cell survival.Non-small cell lung cancer cells become dependent on these survival signals.Gefitinib's inhibition of the survival signals may be a contributing factor to its efficacy as a drug for non-small cell cancer treatment.